SLNO · Soleno Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.20M | - | $1.14M | $696.0K | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $11.27M | - | $8.40M | $9.15M | $13.52M | - | $30.14M | $12.34M | $14.60M | - |
| SG&A | $50.37M | - | $49.20M | $10.89M | $8.47M | - | $49.20M | $10.89M | $8.47M | - |
| Total Operating Expenses | $63.33M | - | $43.91M | $39.18M | $45.74M | - | $80.21M | $24.87M | $23.48M | - |
| D&A | $514.0K | - | $500.0K | $494.0K | $504.0K | - | - | - | $490.0K | - |
| Operating Income | $31.28M | - | $22.11M | ($6.53M) | ($45.74M) | - | ($80.21M) | ($24.87M) | ($23.48M) | - |
| Interest Expense | $1.29M | - | $1.39M | $1.38M | $1.36M | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | $31.38M | - | $26.01M | ($4.71M) | ($43.77M) | - | ($76.62M) | ($21.85M) | ($21.40M) | - |
| EPS - Basic | $0.60 | - | $0.49 | ($0.09) | ($0.95) | - | ($1.83) | ($0.57) | ($0.59) | - |
| EPS - Diluted | $0.59 | - | $0.47 | ($0.09) | ($0.95) | - | ($1.83) | ($0.57) | ($0.59) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $133.03M | $70.11M | $246.66M | $76.50M | $81.33M | $87.93M | $48.41M | $57.02M | $42.85M | $169.68M |
| Accounts Receivable | $47.14M | $28.21M | $25.51M | $24.62M | - | - | - | - | - | - |
| Inventory | $17.31M | $15.02M | $6.67M | $2.35M | - | - | - | - | - | - |
| Accounts Payable | $12.39M | $12.44M | $8.14M | $6.22M | $5.48M | $8.88M | $6.24M | $3.72M | $8.02M | $3.15M |
| Current Assets | $326.38M | $355.81M | $534.85M | $316.79M | $308.92M | $293.89M | $258.20M | $267.50M | $151.22M | $171.36M |
| Total Assets | $608.39M | $563.83M | $599.89M | $332.31M | $318.09M | $330.97M | $296.71M | $304.13M | $168.84M | $180.69M |
| Current Liabilities | $58.05M | $61.36M | $33.25M | $20.94M | $15.73M | $18.75M | $14.96M | $9.15M | $13.46M | $11.51M |
| Long-term Debt | $49.87M | - | $49.85M | $49.84M | $49.84M | $49.83M | - | - | - | - |
| Total Liabilities | $112.59M | $113.72M | $105.09M | $92.17M | $85.83M | $85.86M | $32.01M | $23.37M | $25.45M | $23.18M |
| Stockholders' Equity | $495.80M | $450.12M | $494.81M | $240.14M | $232.26M | $245.11M | $264.70M | $280.76M | $143.39M | $157.51M |
| Retained Earnings | ($399.99M) | ($431.37M) | ($474.73M) | ($500.74M) | ($496.03M) | ($452.26M) | ($396.28M) | ($319.66M) | ($297.81M) | ($276.41M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $25.98M | - | - | - | ($32.75M) | - | - | - | ($12.53M) | - |
| Investing Cash Flow | $37.98M | - | - | - | $22.94M | - | - | - | ($115.24M) | - |
| Financing Cash Flow | ($1.04M) | - | - | - | $3.22M | - | - | - | $938.0K | - |
| CapEx | $40.0K | - | - | - | $5.0K | - | - | - | $11.0K | - |
| Free Cash Flow | $25.94M | - | - | - | ($32.76M) | - | - | - | ($12.54M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.83 | - | - | - | 0.75 | - | - | - | 0.59 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 5.2% | - | 4.3% | -1.4% | -13.8% | - | -25.8% | -7.2% | -12.7% | - |
| Return on equity | 6.3% | - | 5.3% | -2.0% | -18.8% | - | -28.9% | -7.8% | -14.9% | - |
| Return on invested capital | 5.7% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.62 | 5.80 | 16.08 | 15.13 | 19.64 | 15.68 | 17.26 | 29.24 | 11.23 | 14.89 |
| Quick ratio | 5.32 | 5.55 | 15.88 | 15.01 | 19.64 | 15.68 | 17.26 | 29.24 | 11.23 | 14.89 |
| Cash ratio | 2.29 | 1.14 | 7.42 | 3.65 | 5.17 | 4.69 | 3.24 | 6.23 | 3.18 | 14.75 |
| Leverage | ||||||||||
| Debt / Equity | 0.10 | - | 0.10 | 0.21 | 0.21 | 0.20 | - | - | - | - |
| Debt / Assets | 0.08 | - | 0.08 | 0.15 | 0.16 | 0.15 | - | - | - | - |
| Debt / EBITDA | 1.57 | - | 2.21 | - | - | - | - | - | - | - |
| Interest coverage | 24.2x | - | 15.9x | -4.7x | -33.6x | - | - | - | - | - |
| Equity multiplier | 1.23 | 1.25 | 1.21 | 1.38 | 1.37 | 1.35 | 1.12 | 1.08 | 1.18 | 1.15 |
| Liabilities / Assets | 0.19 | 0.20 | 0.18 | 0.28 | 0.27 | 0.26 | 0.11 | 0.08 | 0.15 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.07 | - | 0.17 | 0.30 | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 5273d | - | 2135d | 1235d | - | - | - | - | - | - |
| Days payable outstanding | 3774d | - | 2606d | 3260d | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 56.7x | - | 143.8x | - | - | - | - | - | - | - |
| P / B | 3.6x | - | 7.5x | 17.6x | 14.2x | - | 8.0x | 5.6x | 10.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | 53.3x | - | 155.5x | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | 73.8% | -94.9% | - | -672.6% | -188.4% | -177.2% | - |
| Net income growth (YoY) | - | - | - | 78.5% | -104.6% | - | -605.4% | -157.9% | -156.1% | - |
| EPS growth (YoY) | - | - | - | 84.2% | -61.0% | - | -92.6% | 29.6% | 33.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -161.2% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 113.5% | 83.6% | 86.9% | -14.5% | 62.0% | 55.6% | 1040.0% | 2159.4% | 5333.3% | 1422.1% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SOLENO THERAPEUTICS INC against the 5 most active filers in the same SIC group.